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A B S T R A C T
According to WHO classification follicular lymphoma (FL) is a neoplasm composed of follicle centre (germinal cen-
tre) B-cells, which usually has at least a partially follicular pattern. Bone marrow (BM) infiltration by lymphoma occurs
in 40-70% of cases at the time of diagnosis. The characteristic chromosomal translocation of follicular lymphoma is
t(14;18)(q32;q21) with transposition of BCL2 oncogene to the regulatory region of immunoglobulin heavy chain gene
IgH. Aim of this study was to determine the frequency of PCR detection of IgH/BCL2 in DNA samples isolated from ar-
chival cytological slides of lymph node aspirates, bone marrow and/or peripheral blood (PB) obtained from patients with
histologicaly confirmed follicular lymphoma using primers and protocol proposed by BIOMED-2 consortium. We also
compared molecular with cytomorphological findings in bone marrow/peripheral blood and tested this method of detec-
tion of IgH/BCL2 molecular marker in monitoring minimal residual disease (MRD) in routine clinical setting. DNA
was successfully isolated from all archival cytological slides obtained by fine needle aspiration of lymph nodes as well as
from 75% of smears of bone marrow aspirates from 19 patients. Fusion oncogene was detected in 10 of 19 patients (52%).
For patients with PCR IgH/BCL2 positive lymph nodes, molecular test found BM infiltration in 5 cases (83%), while
cytomorphology detected infiltration in three of eight cases (37%) available for comparison. May-Grünwald-Giemsa stai-
ned cytological smears can be used for PCR-based ancillary methods and the rate of detection of IgH/BCL2 rearrange-
ment is similar to results reported for paraffin-embedded tissues. For patients with detectable baseline molecular marker,
PCR is a highly suitable method for detection of bone marrow involvement and monitoring MRD.
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Introduction
According to WHO classification follicular lymphoma
(FL) is a neoplasm composed of follicle centre (germinal
centre) B-cells, which usually has at least a partially
follicular pattern1. These neoplasms account for almost
30% of all non-Hodgkin lymphomas, and vast majority
(80–90%) are low-grade lymphomas (grade 1–2), which,
by consensus, should be separated from grade 3 lympho-
mas. FL typically affects lymph nodes, but spleen, bone
marrow and peripheral blood are also frequently in-
volved. Bone marrow (BM) infiltration by lymphoma oc-
curs in 40–70% of cases at the time of diagnosis, with
only 1/3 of the patients being in stage I or II at that time.
The characteristic chromosomal translocation of folli-
cular lymphoma is t(14;18)(q32;q21) with transposition
of BCL2 oncogene to the regulatory region of immuno-
globulin heavy chain gene IgH. It is present in approxi-
mately 90% of grade 1–2 FL, but it is much less frequent
in grade 3 follicular lymphomas2. Reported frequencies
depend on the technique used for detection3,4. Polymer-
ase chain reaction (PCR) is a sensitive molecular test but
detection of IgH/BCL2 fusion gene by PCR can fail due to
the genomic variability of the breakpoints in BCL2 gene
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on chromosome 185. Approximately 60% of BCL2 break-
points are located in major breakpoint region (MBR) and
5–25% in minor cluster region (mcr), but other break-
points have been found. Taking into account this inher-
ent relative weakness of molecular designs for the varia-
ble genomic structure of the target oncogene, significant
effort has been put in designing optimal molecular PCR
based test for IgH/BCL2 detection. BIOMED-2 PCR pro-
tocol is recommended for t(14;18) detection and if posi-
tive in primary tumour, it becomes a valuable tool for
precise monitoring of patient’s disease6.
Aim of this study was to determine the frequency of
detection of t(14;18) by consensus BIOMED-2 PCR assay
for IgH/BCL2 fusion gene on DNA isolated from archived
cytological slides of primary tumours (lymph nodes),
bone marrow and/or peripheral blood (PB) obtained from
patients with histologicaly confirmed follicular lympho-
ma. We also sought to compare molecular with cytomor-
phological findings in bone marrow and/or peripheral
blood of FL patients and we tested the value of this
method of detection of IgH/BCL2 molecular marker in
monitoring minimal residual disease (MRD) in BM and/
or PB compartment after immuno and cytotoxic therapy.
Materials and Methods
Cytological smears of lymph node aspirates from 19
patients with histologicaly confirmed diagnoses of folli-
cular lymphoma were randomly selected from our ar-
chive and reviewed for diagnosis and celularity. Clinical
data for these patients are shown in Table 1. Clinical re-
sponse criteria were defined according to revised re-
sponse criteria for malignant lymphoma7. Specimens were
obtained by fine needle aspiration (FNA) for diagnostic
purposes8 and slides were stored for 2–10 years. Two to
four air-dried May-Grünwald Giemsa stained slides per
case were selected for DNA extraction. DNA was isolated
by previously described method according to standard
phenol/chloroform procedure9,10. Patients with detected
baseline molecular marker, had molecular monitoring
during the follow up period performed on either fresh
BM and/or PB cells or from archived cytological slides of
those samples, when available (Table 2). PCR detection
of the IgH/BCL2 rearrangement with amplification of
the MBR, mcr and 3’MBR breakpoint regions was per-
formed using the primers and protocol proposed by
BIOMED-2 consortium6. Special attention was paid to
prove that quality of DNA obtained from archived glass
slides of cytological preparations was adequate for PCR
and this was done by amplification of Abl as the control
gene.
Results
Clinical characteristics of patients with FL, including
histological grade, clinical staging and results of
BIOMED-2 PCR performed on DNA obtained from lym-
ph nodes are presented in Table 1. There were 15 females
and four male patients, aged 25–73 years (median 53
years). Fifteen patients had low-grade (grade 1 and 2)
lymphoma while only 4 patients were classified as folli-
cular lymphoma grade 3. At the time of diagnosis, 2/3 of
the patients were in clinical stage (CS) III and IV. Abl
housekeeping gene amplification was successful in all
samples of DNA isolated from archival cytological slides
obtained by FNA of lymph nodes of 19 patients with FL
at the time of diagnosis. BIOMED-2 IgH/BCL2 protocol
has detected fusion oncogene in 10 of 19 patients (52%).
Eight PCR-positive patients (80%) had low-grade FL.
Two of four (50%) grade 3 FL patients were IgH/BCL2
positive (Table 1). Except for one, all patients exhibited
BCL2MBR type breakpoint. For eight patients with PCR
IgH/BCL2 positive lymph nodes the same molecular test
was performed on DNA isolated from cytological slides of
BM aspirates (and PB when available) at the time of di-
agnosis and some time after therapy (Table 2). Example
of agarose gel electrophoresis results is shown in the Fig-
ure 1. Two of analyzed BM samples (25 %) were consid-
ered technically inadequate for molecular analysis (No
10 and 14), as there was no amplification of the control
gene. Molecular test found BM infiltration in 5 out of six
cases (83%) with good quality DNA, while cytomorpho-
logy detected infiltration in three of eight examined cases
(37%) at the time of diagnosis (Table 2). Of the two pa-
tients with PCR-detectable molecular marker in BM at
initial staging and who were available for molecular fol-
low up, one (Number 1) remained positive after immuno-
cytotherapy although in clinical remission (CR) and with
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TABLE 1
CLINICAL AND MOLECULAR CHARACTERISTICS OF
FOLLICULAR LYMPHOMA PATIENTS
Patient
No
Age Gender Grade
Clinical
Stage
Lypmh
nodes
PCR
1 56 F 1 IIA/B +
2 42 F 2 IIA +
3 48 F 2 IIIA +
4 37 F 1 IVA –
5 67 F 3 IIIA –
6 25 M 3 IIA +
7 52 F 1 IVA/B –
8 48 F 1–2 IVA –
9 57 M 1 IVA/B –
10 67 F 1 IVA/B +
11 46 F 1 IVB +
12 57 M 1 IVA/B –
13 51 F 3 IVA/B –
14 71 F 1 IVA/B +
15 52 F 1 IIA –
16 48 F 3 IIA +
17 58 M 1 IVA/B –
18 52 F 1 IIA/B +
19 73 F 1 IVA +
clearing of the infiltrate as detected by cytomorphology.
The second patient (Number 18) became PCR-negative
after therapy. Cytomorphology failed to detect infiltra-
tion of BM for this patient both at initial staging and af-
ter therapy (Table 2). A single patient with PCR and
cytomorphologicaly negative bone marrow (Number 2)
remained negative and is in prolonged complete remis-
sion. One patient with stage IVB (Number 14) had ag-
gressive disease and was treated with several lines of
immuno (MabThera®) and cytotoxic therapies for resis-
tant disease. She was both PCR and morphologically con-
stantly positive in BM and PB and had succumbed to the
disease. Summarized, PCR is superior to cytomorphology
in detecting lymphoma infiltration of BM at the time of
diagnosis. This advantage is retained or is even more evi-
dent in evaluating the same compartment after immuno
or cytotoxic therapy of FL.
Discussion and Conclusion
Molecular markers in haematologic malignancies,
when present, are used for establishing diagnosis, con-
tribute to process of clinical staging (evaluation of in-
volvement of BM or PB), serve as prognostic factors and
are useful for detection of minimal residual disease. De-
tection of t(14;18) is not required for establishing diagno-
sis of FL, but may prove important for confirmation of di-
agnosis when standard analyses are inconclusive. FISH
and PCR are molecular cytogenetic methods regularly
used for detection of t(14;18)(q32;q21) with formation of
the fusion oncogene IgH/BCL2 in follicular lymphomas.
Although PCR is the most sensitive and specific molecu-
lar test for detection of genetic aberrations occurring
through chromosome rearrangements, in FL it detects
the specific genetic marker in only 50–70% of cases at
diagnosis11,12. On the other hand, interphase FISH is
more sensitive because it can detect breakpoints occur-
ring outside regions covered by PCR and confirms
t(14;18) in 90% FLs harbouring this rearrangement in
its karyotype13,14. While this fact is of advantage at the
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TABLE 2
MOLECULAR AND CYTOMORPHOLOGICAL MONITORING OF IGH/BCL2 POSITIVE PATIENTS (BONE MARROW AND PERIPHERAL
BLOOD)
Patient No
At diagnosis After therapy at Current status
PCR Cytology PCR Cytology
1
    +1m CR
  
2
    +24m CR
  
6
   +1m CR
   +24m
10
*    +8m PR
   +24m
11
   +2m CR
  
14
*    +1m died at +2m
  
18
    +1m CR
  
19
   +12m PR
   +12m
 PB – peripheral blood positive, PB – peripheral blood negative,  BM – bone marrow positive, BM – bone marrow negative, CR
– complete response, PR – partial response, * – no amplification of the control gene, +m – month after therapy
Fig. 1. Representative agarose gel electrophoresis of IgH-BCL2
PCR amplicons M-molecular weight marker 100bp-allelic lad-
der, 1,2-lymph node (smear sample), 3-bone marrow, weak posi-
tive (smear sample), 4-lymph node (fresh FNA aspirate), 5-pe-
ripheral blood, 6-negative control, water blank.
time of diagnosis, it is less useful for monitoring the dis-
ease throughout the treatment. If PCR can detect IgH/
BCL2 in primary tumour, high sensitivity and specificity
make this method a valuable tool for monitoring patients
with FL and detection of MRD15. It is also well known
that paraffin-embedded tissue samples are reliable sour-
ce of DNA for molecular analysis16–18. In our study we
have shown that air-dried, routinely stained and stored
cytological specimens can also provide material for mo-
lecular analysis as 100% of lymph node material and 75%
of bone marrow specimens had good quality DNA pre-
served (Table 1 and 2). The length of time slides have
been stored didn’t have impact on DNA amplification.
For two samples of the bone marrow specimens that did-
n’t amplify housekeeping gene the reason for failure is
not clear. Unexpected advantage of the method was that
even slides that were less satisfactory for morphology
and not suitable for other ancillary techniques such as
immunocytochemistry due to large numbers of naked
nuclei, were a good source of DNA. Cytological slides
have already been evaluated for DNA extraction7,9, but to
our knowledge detection of IgH/BCL2 translocation was
not examined. Espinet observed IgH/BCL2 translocation
in 59% of FL using PCR BIOMED-2 protocol on DNA iso-
lated from paraffin-embedded tissue, and Belaud-Rotu-
reau had similar results on frozen and paraffin-embed-
ded tissue11,12. In our study frequency of detection of
IgH/BCL2 in lymph nodes was 52%, and of 15 low-grade
follicular lymphomas 53% were positive, in keeping with
reported results.
According to WHO classification, bone marrow infil-
tration occurs in 40–70% of FL cases at presentation, but
depending on the method used for evaluation, bone mar-
row is infiltrated with lymphoma cells in majority of
cases of follicular lymphoma at initial staging even if
there is no evidence of involvement based on morphologi-
cal evaluation only. Most cases of indolent lymphoma
eventually relapse despite treatments, probably because
of persistence of malignant cells that are undetectable by
conventional methods. PCR-based methods are increas-
ingly used for minimal residual disease detection, as they
have higher sensitivity compared to morphological and
immunophenotyping techniques19. Several studies sho-
wed that molecular response after conventional chemo-
therapy with or without rituximab (antiCD20Ab) was fa-
vourable prognostic factor20,21. In our series of available
patients, molecular test detected MRD where cytomor-
phology did not have proof of persisting neoplastic cells.
BM clearance was found by PCR in one case, three cases
remained positive and three were not available for moni-
toring of MRD in bone marrow. Of three cases positive af-
ter therapy, two are in clinical remission and one patient
had succumbed to the disease.
In conclusion, we can state that MGG stained cytologi-
cal smears can be useful as a source of DNA for PCR-
-based ancillary methods especially in cases where amount
and quality of diagnostic material is limited. Frequency
of detection of IgH/BCL2 rearrangement is similar to re-
sults reported for paraffin-embedded tissues. Although
on limited number of cases, we have confirmed that cur-
rent consensus IgH/BCL2 BIOMED-2 PCR test is not op-
timal method for the detection of translocation t(14;18)
in follicular lymphoma, but for PCR-positive cases it is a
highly suitable method for detection of bone marrow in-
volvement and monitoring MRD.
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PCR ZA OTKRIVANJE IGH/BCL2 PREUREDBE S ARHIVSKIH CITOLO[KIH RAZMAZA PUNKTATA
FOLIKULARNIH LIMFOMA
S A @ E T A K
Prema klasifikaciji Svjetske zdravstvene organizacije, folikularni limfomi su tumori stanica centra folikula koji bar
djelomice zadr`avaju folikularni na~in rasta. Infiltracija ko{tane sr`i nalazi se u 40–70% slu~ajeva u vrijeme postav-
ljanja dijagnoze. Karakteristi~na kromosomska translokacija folikularnih limfoma je t(14;18)(q32;q21) koja premje{ta
BCL2 onkogen pod kontrolu promotorske regije za te{ke lance imunoglobulina IgH na kromosomu 14. Cilj ovog rada
bio je odrediti u~estalost translokacije t(14;18) molekularnom analizom temeljenom na polimeraza lan~anoj reakciji
(PCR) u uzorcima DNA izoliranim s arhivskih citolo{kih stakala koriste}i standardizirani analiti~ki protokol Europske
radne grupe BIOMED-2, usporediti molekularne i citomorfolo{ke nalaze te ispitati vrijednost metode za pra}enje mi-
nimalne ostatne bolesti (MRD) u svakodnevnim uvjetima. Izolacija DNA je uspjela sa svih citolo{kih razmaza punktata
limfnih ~vorova kao i u 75% razmaza punktata ko{tane sr`i, a PCR-om je otkrivena IgH/BCL2 preuredba u 10 od 19
(52%) bolesnika. U bolesnika s pozitivnim molekularnim testom u limfnom ~voru, PCR-om je prona|ena infiltracija
ko{tane sr`i limfomom u 5 bolesnika (83%), dok je citolo{ka analiza infiltraciju na{la u 3 od osam uzoraka dostupnih za
usporedbu. Citolo{ki razmazi bojani May-Grünwald Giemsa metodom (MGG) dobar su izvor DNA za metode mole-
kularne analize temeljene na lan~anoj reakciji polimeraze. U~estalost otkrivanja IgH/BCL2 preuredbe odgovara re-
zultatima studija ra|enih na histolo{kim uzorcima. U bolesnika u kojih je prona|ena translokacija u dijagnosti~kim
uzorcima, PCR je pogodna metoda za otkrivanje infiltracije ko{tane sr`i limfomom te za pra}enje minimalne ostatne
bolesti.
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